Fennec Pharmaceuticals Inc (FENC)
6.81
+0.05
(+0.74%)
USD |
NASDAQ |
Jun 17, 16:00
6.80
-0.01
(-0.15%)
Pre-Market: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 186.06M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -27.86% |
Valuation | |
PE Ratio | 227.00 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 4.199 |
Price to Book Value | 61.73 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 10.40 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 72.85% |
Profile
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States. |
URL | https://www.fennecpharma.com |
Investor Relations URL | https://investors.fennecpharma.com/ |
HQ State/Province | North Carolina |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | Aug. 02, 2024 (est.) |
Last Earnings Release | May. 14, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States. |
URL | https://www.fennecpharma.com |
Investor Relations URL | https://investors.fennecpharma.com/ |
HQ State/Province | North Carolina |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | Aug. 02, 2024 (est.) |
Last Earnings Release | May. 14, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |